uniQure N.V. (QURE) stock
QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30217% above fair value
$20.23−0.07 (-0.34%)
Close on Nov 19, 2026Market cap $1.40BP/E –Yield –
uniQure operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
uniQure's operating income for the twelve months ending Jun 30, 2026 was -$200.08M. For fiscal 2025 it was -$185.35M. The highest annual figure on record is $310.62M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$185.35M | – |
| FY2024 | Dec 31, 2024 | -$184.29M | – |
| FY2023 | Dec 31, 2023 | -$282.87M | – |
| FY2022 | Dec 31, 2022 | -$143.16M | -146.1% |
| FY2021 | Dec 31, 2021 | $310.62M | – |
| FY2020 | Dec 31, 2020 | -$125.43M | – |
| FY2019 | Dec 31, 2019 | -$121.14M | – |
| FY2018 | Dec 31, 2018 | -$88.23M | – |
| FY2017 | Dec 31, 2017 | -$71.34M | – |
| FY2016 | Dec 31, 2016 | -$71.95M | – |
| FY2015 | Dec 31, 2015 | -$71.15M | – |
| FY2014 | Dec 31, 2014 | -$53.68M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$52.20M | – |
| Q1 FY2026 | Mar 31, 2026 | -$45.72M | – |
| Q4 FY2025 | Dec 31, 2025 | -$51.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$51.04M | – |
| Q2 FY2025 | Jun 30, 2025 | -$43.87M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$45.83M | – |
| Q3 FY2024 | Sep 30, 2024 | -$40.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$44.01M | – |
| Q1 FY2024 | Mar 31, 2024 | -$54.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$61.75M | -333.0% |
| Q3 FY2023 | Sep 30, 2023 | -$81.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$65.07M | – |
| Q1 FY2023 | Mar 31, 2023 | -$74.17M | – |
| Q4 FY2022 | Dec 31, 2022 | $26.50M | +1181.5% |
| Q3 FY2022 | Sep 30, 2022 | -$59.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$56.06M | -114.1% |
| Q1 FY2022 | Mar 31, 2022 | -$54.08M | – |
| Q4 FY2021 | Dec 31, 2021 | $2.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$45.00M | – |
| Q2 FY2021 | Jun 30, 2021 | $398.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.46M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$44.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$38.21M | – |
| Q1 FY2020 | Mar 31, 2020 | -$34.46M | – |
| Q4 FY2019 | Dec 31, 2019 | -$32.98M | – |
| Q3 FY2019 | Sep 30, 2019 | -$31.33M | – |
| Q2 FY2019 | Jun 30, 2019 | -$29.33M | – |
| Q1 FY2019 | Mar 31, 2019 | -$27.50M | – |
| Q4 FY2018 | Dec 31, 2018 | -$24.21M | – |
| Q3 FY2018 | Sep 30, 2018 | -$23.22M | – |
| Q2 FY2018 | Jun 30, 2018 | -$21.20M | – |
| Q1 FY2018 | Mar 31, 2018 | -$19.60M | – |
| Q4 FY2017 | Dec 31, 2017 | -$22.65M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.28M | – |
| Q2 FY2017 | Jun 30, 2017 | -$19.71M | – |
| Q1 FY2017 | Mar 31, 2017 | -$19.72M | – |
| Q4 FY2016 | Dec 31, 2016 | -$16.39M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.16M | – |
See a number that looks wrong?